# A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Source: https://onco.cc/trials/nct05205850/  
OnCo record `nct05205850` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of RC118-ADC in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.

## Summary

A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT05205850 by RemeGen Co., Ltd., with 135 participants planned, started 2022-03-03 and due to reach its primary completion in 2025-09-30. Interventions recorded: RC118-ADC.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05205850
- Phase: 1/2
- Setting: An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors with Positive Expression of Claudin 18.2
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 135

## Sources

- ClinicalTrials.gov NCT05205850: https://clinicaltrials.gov/study/NCT05205850

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [RC118-ADC](https://onco.cc/drugs/rc118-adc/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct05205850.json